| 标题： | 中成药治疗成人社区获得性肺炎临床应用指南 |
| title： | Clinical practice guideline on treating community-acquired pneumonia in adult patients with Chinese patent medicines |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 中医药指南 |
| classification： | Traditional Chinese Medicine guideline |
| 领域： | 治疗 |
| field： | Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 本指南适用于治疗社区获得性肺炎的医务人员、卫生公共人员和科研工作者。 |
| Guide users： | This guideline can be applied to medical personnel, public health personnel, scientific research works who treat community-acquired pneumonia. |
| 证据分级方法： | GRADE provides a way to assess the quality of evidence and the strength of recommendations for clinical practice guidelines. We will import the evidence of Chinese patent medicine for the treatment of adult community-acquired pneumonia into the GRAED system, collect and evaluate the quality of the evidence, make a summary of the evidence, and finally form a recommendation opinion. We evaluated the quality of evidence based on the risk of bias, inconsistency, indirectness, imprecision, and publication bias. The quality of evidence was classified as high, moderate, low, or very low quality. Moreover, comprehensively consider the balance of benefit and harms, evidence quality, cost, clinical feasibility, availability and clinical acceptability according to GRADE method suggestions. The recommendation intensity of recommendations is divided into "strong recommendation" and "weak recommendation". |
| Evidence grading method： | |
| 制定单位： | 河南中医药大学第一附属医院 |
| Formulating unit： | The First Affiliated Hospital of Henan University of Chinese Medicine |
| 注册时间： | 2021-06-15 |
| Registration time： | |
| 注册编号： | IPGRP-2021CN155 |
| Registration number： | |
| 指南制订的目的： | 社区获得性肺炎（Community-acquired pneumonia，CAP）作为威胁人类健康的常见感染性疾病，给社会和个人造成了巨大的负担。用于治疗CAP的抗感染药物极易产生耐药株，尽管诊断技术在不断进步，新型抗菌药物在陆续上市，但CAP的发病率和病死率仍然较高。中成药辅助治疗CAP具有独特的优势，可发挥减毒、增效的作用，其疗效已经在临床实践和文献中得到了证实。但是目前缺乏循证医学证据评价及治疗推荐，尚无指南或标准供遵循和参考，在一定程度上限制了中成药治疗CAP的疗效发挥。因此，有必要制定中成药治疗CAP的临床应用指南，以全面推广中成药在CAP中的应用，充分规范临床诊疗，提高CAP的治疗水平，减轻疾病负担。 |
| Purpose of the guideline： | Community-acquired pneumonia is a common infectious disease threatening human health, imposes a huge burden on society and individuals. Antimicrobial agents used to treat CAP are prone to drug-resistant strains. Despite the continuous progress in diagnostic techniques and the continuous introduction of new antimicrobial agents, the morbidity and fatality rates of CAP remain high. The adjuvant treatment of CAP with Chinese patent medicine has unique advantages, which can play the role of reducing toxicity and enhancing efficacy, and its efficacy has been confirmed in clinical practice and literature. However, there is a lack of evidence-based medicine evidence evaluation and treatment recommendation, and there are no guidelines or standards to follow and refer to, which to some extent limits the efficacy of proprietary Chinese medicine in treating CAP. Therefore, it is necessary to develop guidelines for clinical application of proprietary Chinese medicine in CAP, so as to fully promote the application of proprietary Chinese medicine in CAP, fully regulate clinical diagnosis and treatment, improve the treatment level of CAP, and reduce the burden of disease. |
